Evidence map›Paper›PMID 25385064›Full record

ArticleImmunology and cell biology2015

C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells.

Anne S De Groot, Ted M Ross, Lauren Levitz, Timothy J Messitt, Ryan Tassone, Christine M Boyle, Amber J Vincelli, Leonard Moise, William Martin, Paul M Knopf

Open access · greenAbstract read
In one paragraph

Article in Immunology and cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Modular complement assemblies for mitigating inflammatory conditions.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Complement factor H in host defense and immune evasion.Cellular and molecular life sciences : CMLS · 2017
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Anne S De Groot1] EpiVax Inc., Providence, RI, USA [2] Institute for Immunology and Informatics, Department of Cell and Molecular Biology, University of Rhode Island, Providence, RI, USA.ORCID 0000000159111459
Ted M RossVaccine and Gene Therapy Institute of Florida, Port Saint Lucie, FL, USA.
Lauren LevitzEpiVax Inc., Providence, RI, USA.
Timothy J MessittEpiVax Inc., Providence, RI, USA.
Ryan TassoneEpiVax Inc., Providence, RI, USA.
Christine M BoyleEpiVax Inc., Providence, RI, USA.
Amber J VincelliEpiVax Inc., Providence, RI, USA.
Leonard Moise1] EpiVax Inc., Providence, RI, USA [2] Institute for Immunology and Informatics, Department of Cell and Molecular Biology, University of Rhode Island, Providence, RI, USA.
William MartinEpiVax Inc., Providence, RI, USA.
Paul M KnopfEpiVax Inc., Providence, RI, USA.
Providence College · USUniversity of Rhode Island · USVaccine & Gene Therapy Institute of Florida · US

Funding

TRIAD Scientific Core: TRIAD ToolkitU19AI082642 · NIAID · UNIVERSITY OF RHODE ISLAND · PI MARTIN, WILLIAM D · 2009 to 2013
$13.0M
NIAID NIH HHS NIH U19AI082642NIAID NIH HHS U19 AI082642
6 · The paper itself

Abstract

Complement fragment C3d covalently attached to antigens enhances immune responses, particularly for antigens lacking T-cell epitopes. Enhancement has been attributed to receptor cross-linking between complement receptor CR2 (CD21) and polysaccharide antigen to surface IgM on naïve B cells. Paradoxically, C3d has still been shown to increase immune responses in CD21 knockout mice, suggesting that an auxiliary activation pathway exists. In prior studies, we demonstrated the CD21-independent C3d adjuvant effect might be due to T-cell recognition of C3d T-helper epitopes processed and presented by major histocompatibility complex class II on the B-cell surface. C3d peptide sequences containing concentrated clusters of putative human C3 T-cell epitopes were identified using the epitope-mapping algorithm, EpiMatrix. These peptide sequences were synthesized and shown in vitro to bind multiple human leukocyte antigen (HLA)-DR alleles with high affinity, and induce interferon-γ responses in healthy donor peripheral blood mononuclear cells. In the present studies, we establish further correlations between HLA binding and HLA-specific lymphocyte reactions with select epitope clusters. In addition, we show that the T-cell phenotype of C3d-specific reactive T cells is CD4(+)CD45RO(+) memory T cells. Finally, mutation of a single T-cell epitope residing within the P28 peptide segment of C3d resulted in significantly diminished adjuvant activity in BALB/c mice. Collectively, these studies support the hypothesis that the paradoxical enhancement of immune responses by C3d in the absence of CD21 is due to internalization and processing of C3d into peptides that activate autoreactive CD4(+) T-helper cells in the context of HLA class II.

Indexed as

Lymphocyte ActivationAdjuvants, ImmunologicAmino Acid SequenceAnimalsCD4-Positive T-LymphocytesComplement C3dComputer SimulationEpitopes, T-LymphocyteFemaleGene TargetingHistocompatibility AntigensHumansImmunologic MemoryInterferon-gammaMice, Inbred BALB CMolecular Sequence DataAdjuvants, ImmunologicComplement C3dEpitopes, T-LymphocyteHistocompatibility AntigensInterferon-gammaPeptides

Identifiers

PMID25385064
PMCPMC4323994
OpenAlexW2027525817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.